Yoda Therapeutics Inc. (YODA), an AI-driven company that focuses on Central Nervous System (CNS) drugs, today announced the dosing of the first patient in the Phase 2 trial of YA-101 for Multiple System Atrophy (MSA) in the United States.

MSA is a rare and rapidly progressive neurodegenerative disorder that causes severe motor impairment (parkinsonism or cerebellar ataxia) accompanied by autonomic dysfunction, leading to a significant decline in patients' quality of life. Currently, no disease-modifying therapies exist to reverse or slow the progression of MSA, and symptomatic management offers limited relief and is not a practical long-term solution.

YA-101, a novel chemical entity (NCE), is designed to treat neurodegenerative diseases by inhibiting neuroinflammation and enhancing neural plasticity. Following the successful completion of safety and tolerability assessments in Phase 1 clinical trial with healthy volunteers in Australia, YA-101 has entered Phase 2 trial, which aims to evaluate the safety, tolerability, pharmacokinetics, and efficacy of YA-101 in subjects with MSA at multiple sites in the United States and Taiwan. This Phase 2 trial is a randomized, double-blind, placebo-controlled investigation for MSA patients with walking ability, including those who need walking assistance. Measurement of clinical symptoms, biomarkers, and imaging will allow a comprehensive assessment. Further details are available at https://clinicaltrials.gov/study/NCT06848231.

"The dosing of our first patient in the Phase 2 clinical trial of YA-101 for Multiple System Atrophy represents a big step forward as we strive to bring a much-needed treatment option to individuals affected by this rare and debilitating neurodegenerative disorder." stated Yufeng Jane Tseng, PhD, Chief Executive Officer of YODA.

Source: prnewswire.com

Report Abuse